Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis

Dermatologic Therapy
Toral Patel, Kenneth B Gordon

Abstract

The next generation of targeted biologic therapies for psoriasis will either be directed against new protein targets or improve on the efficacy, safety, or convenience of medications available for an already validated area in the immune response. Adalimumab is a fully human monoclonal antibody directed against tumor necrosis factor-alpha, a central cytokine in the immune response in psoriasis that has already been shown to be an effective target for therapy. This medication is approved by the US Food and Drug Administration (USFDA) for the treatment of rheumatoid arthritis. Early phrase II studies with adalimumab have shown excellent efficacy for psoriasis with either weekly or every other week subcutaneous injection. Moreover, the safety and tolerability of adalimumab in large clinical studies of rheumatoid arthritis have shown good results. Thus, adalimumab shows significant promise for the therapy of psoriasis in the future.

References

Sep 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L MellemkjaerJ H Olsen
Mar 22, 2001·The New England Journal of Medicine·E H Choy, G S Panayi
Nov 14, 2001·Dermatologic Clinics·J R LaDuca, A A Gaspari
Jan 10, 2002·Annals of the Rheumatic Diseases·D Pyne, D A Isenberg
May 22, 2002·Archives of Dermatology·Prashant SingriKenneth B Gordon
Mar 5, 2003·The Lancet Infectious Diseases·Michael A GardamDonald C Vinh
Aug 2, 2003·Journal of the American Academy of Dermatology·Alice B Gottlieb
Feb 18, 2004·Archives of Dermatology·Gerald Krueger, Kristina Callis

❮ Previous
Next ❯

Citations

May 12, 2007·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·G Wozel, M Sticherling
Mar 8, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Christopher KnightRobert Boggs
May 3, 2005·Journal of Dermatological Science·John Koo, Pooja Khera
Jan 26, 2010·Actas dermo-sifiliográficas·R K H MakF O Nestle
Oct 14, 2006·Annals of the Rheumatic Diseases·D E FurstM H Weisman
May 16, 2007·The Journal of Investigative Dermatology. Symposium Proceedings·Alice B Gottlieb
Feb 5, 2008·Mayo Clinic Proceedings·Sotirios TsiodrasDimitrios P Kontoyiannis
Jul 25, 2009·Journal of the American Academy of Dermatology·Aikaterini-Evaggelia MoustouAlexander J Stratigos
Feb 24, 2007·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Benjamin F Chong, Henry K Wong
Jul 21, 2005·The British Journal of Dermatology·S DalleL Thomas
Feb 19, 2009·Dermatologic Therapy·Xinaida T LimaAlexandra B Kimball
Oct 26, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·A JacobiM Hertl
Feb 20, 2007·Clinical and Experimental Dermatology·G PitarchJ M Fortea
Oct 31, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·A MarchesoniA Giannetti
Jul 7, 2015·International Journal of Dermatology·Virendra N SehgalAnanta Khurana
Jul 16, 2005·Journal of the American Academy of Dermatology·Valencia D ThomasJoseph C Kvedar
Jun 22, 2005·Journal of the American Academy of Dermatology·Gerald Krueger, Charles N Ellis
Aug 3, 2010·The Journal of Dermatological Treatment·Meghan T Hession, Alice B Gottlieb
Aug 24, 2006·Expert Opinion on Pharmacotherapy·Bart J F van den BemtRob Janknegt
Sep 14, 2007·The Journal of Dermatological Treatment·H Jorn BovenschenMarieke M B Seyger
Oct 6, 2005·Dermatology : International Journal for Clinical and Investigative Dermatology·A M ThielenJ-H Saurat
Jul 8, 2014·Dermatitis : Contact, Atopic, Occupational, Drug·Noori KimPamela L Scheinman
May 20, 2005·Seminars in Cutaneous Medicine and Surgery·Kevin R SteinSteven R Feldman
Jan 16, 2010·International Journal of Immunopathology and Pharmacology·G CaldarolaC Feliciani
Dec 21, 2013·International Journal of Immunopathology and Pharmacology·C Nardis
Jan 27, 2017·Frontiers in Immunology·Alexandros MitsiosKonstantinos Ritis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.